Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACAD | US
-0.03
-0.20%
Healthcare
Biotechnology
30/06/2024
04/10/2024
15.10
14.89
15.13
14.72
ACADIA Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics Inc. to discover develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Midcap (2B - 10B USD)
Weak P/E, and PEG ratio indicator
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
25.1%1 month
25.8%3 months
50.3%6 months
43.9%82.58
20.12
5.04
0.11
0.06
63.00
2.42
-0.42
34.27M
2.50B
2.50B
-
12.58
2.83K
46.40
6.70
7.26
7.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.86
Range1M
2.13
Range3M
4.71
Rel. volume
0.90
Price X volume
18.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 28.4 | 2.66B | 4.18% | n/a | 0.98% |
Zai Lab Limited | ZLAB | Biotechnology | 26.36 | 2.63B | 2.93% | n/a | 11.88% |
Protagonist Therapeutics Inc | PTGX | Biotechnology | 44.37 | 2.61B | -1.36% | 16.38 | 2.03% |
Geron Corporation | GERN | Biotechnology | 4.32 | 2.60B | -2.70% | n/a | 28.38% |
Verona Pharma plc | VRNA | Biotechnology | 32.01 | 2.60B | 11.49% | n/a | 129.87% |
IDEAYA Biosciences Inc | IDYA | Biotechnology | 29.97 | 2.53B | -5.46% | n/a | 0.20% |
Veracyte Inc | VCYT | Biotechnology | 32.84 | 2.52B | -2.83% | n/a | 1.83% |
Agios Pharmaceuticals Inc | AGIO | Biotechnology | 41.325 | 2.48B | -1.11% | n/a | 9.78% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 42.99 | 2.46B | -1.15% | n/a | 0.51% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 63.00 | 0.76 | Expensive |
Ent. to Revenue | 2.42 | 3,674.48 | Cheaper |
PE Ratio | 82.58 | 38.01 | Expensive |
Price to Book | 5.04 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 50.28 | 74.67 | Lower Risk |
Debt to Equity | 0.11 | -1.82 | Expensive |
Debt to Assets | 0.06 | 0.26 | Cheaper |
Market Cap | 2.50B | 3.73B | Emerging |